GLP-1 for Fatty Liver Disease (MASLD/MASH)

Metabolic dysfunction-associated steatotic liver disease (MASLD) — formerly called non-alcoholic fatty liver disease (NAFLD) — is the most common chronic liver condition worldwide, affecting an estimated 30% of adults globally, with prevalence rising to approximately 38% in data from 2016–2019 [1]. MASLD is defined by the accumulation of excess fat in liver cells (hepatic steatosis) in the context of at least one metabolic risk factor such as obesity, type 2 diabetes, dyslipidemia, or hypertension, and without significant alcohol use. When hepatic steatosis triggers an inflammatory response, the disease advances to metabolic dysfunction-associated steatohepatitis (MASH) — formerly called NASH — which carries meaningful risks of cirrhosis, liver failure, and hepatocellular carcinoma.

Obesity and insulin resistance are the central drivers of MASLD. Excess visceral fat releases free fatty acids into the portal circulation, overwhelming the liver's ability to oxidize or export fat, leading to hepatic triglyceride accumulation. Insulin resistance further promotes de novo lipogenesis and impairs fatty acid oxidation. Progression from simple steatosis to MASH involves added oxidative stress, mitochondrial dysfunction, gut-derived endotoxins, and pro-inflammatory cytokines that activate stellate cells and drive collagen deposition (fibrosis). Fibrosis stage — from F1 (mild) through F4 (cirrhosis) — is the strongest histological predictor of liver-related mortality and progression to end-stage liver disease.

For most of the past two decades, no drug was approved specifically for MASH. Management was limited to lifestyle modification, control of metabolic comorbidities, and treatment of downstream complications. That changed with two approvals in the mid-2020s: resmetirom (Rezdiffra), a liver-targeted thyroid hormone receptor beta agonist, received FDA approval for non-cirrhotic MASH with fibrosis stage F2 or F3 in March 2024 [6], followed by semaglutide (Wegovy 2.4 mg), the first GLP-1 receptor agonist approved for MASH, based on the ESSENCE phase 3 trial results [4].

Interest in GLP-1 receptor agonists for MASH stems from their convergent mechanisms: they promote weight loss (reducing hepatic fat delivery), improve insulin sensitivity, suppress hepatic lipogenesis through direct GLP-1 receptor signaling in the liver, reduce systemic inflammation, and attenuate gut-derived endotoxemia. A 2025 meta-analysis of randomized controlled trials by Mantovani et al. confirmed that, as a class, GLP-1 receptor agonists significantly improve MASH histology and reduce liver fibrosis stage compared with placebo [5].

Phase 2 evidence for semaglutide came from a 72-week randomized trial by Newsome et al. published in the New England Journal of Medicine in 2021 [2]. Among 320 patients with biopsy-confirmed NASH, semaglutide 0.4 mg daily achieved NASH resolution without worsening of fibrosis in 59% of patients, compared with 17% in the placebo group (P<0.001). Mean body weight fell 13% with semaglutide versus 1% with placebo. Notably, fibrosis improvement of at least one stage was seen in 43% of semaglutide patients versus 33% with placebo — a trend that did not reach statistical significance in this phase 2 trial (P=0.48), raising the question of whether the drug's anti-fibrotic effect would prove significant at higher doses or longer duration.

Tirzepatide, the dual GLP-1/GIP receptor agonist, was evaluated in the SYNERGY-NASH phase 2 trial (Loomba et al., N Engl J Med 2024 [3]). Among 190 patients with biopsy-defined MASH and fibrosis stage F1–F3, tirzepatide achieved MASH resolution without worsening of fibrosis in 44% (5 mg), 56% (10 mg), and 62% (15 mg) of patients, compared with 10% in the placebo group (P<0.001 for all doses). Fibrosis improvement of at least one stage occurred in 51% of patients in the 10 mg and 15 mg groups versus 30% with placebo. The dose-response gradient and magnitude of histological improvement were considered clinically meaningful, supporting progression to a phase 3 program.

The ESSENCE phase 3 trial (Sanyal, Newsome, et al., N Engl J Med 2025 [4]) is the pivotal study for semaglutide 2.4 mg weekly in MASH. It enrolled 1,197 patients with biopsy-defined MASH and fibrosis stage F2 or F3 in a 2:1 randomization. Results from a planned interim analysis at week 72 (reported in 800 patients) demonstrated that resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of semaglutide-treated patients versus 34.3% with placebo — a difference of 28.7 percentage points (95% CI 21.1 to 36.2; P<0.001). Reduction in liver fibrosis without worsening of steatohepatitis was achieved in 36.8% of semaglutide patients versus 22.4% with placebo (difference 14.4 percentage points; 95% CI 7.5 to 21.3; P<0.001). The combination of both endpoints — simultaneous MASH resolution and fibrosis reduction — occurred in 32.7% versus 16.1%. Mean body weight declined 10.5% with semaglutide versus 2.0% with placebo. These results led to FDA approval of semaglutide 2.4 mg for MASH, making it the first GLP-1 receptor agonist approved for this liver indication.

Semaglutide 2.4 mg weekly (Wegovy) is now FDA-approved for MASH with fibrosis stage F2 or F3 in adults, based on the ESSENCE trial. Diagnosis requires liver biopsy confirmation of both steatohepatitis (lobular inflammation, hepatocellular ballooning) and non-cirrhotic fibrosis at stage F2 or F3. Non-invasive tests (vibration-controlled transient elastography, serum biomarker panels, MR elastography) can screen for the disease and monitor response, but biopsy remains the gold standard for staging to establish eligibility under the approved indication.

Many MASH patients will also carry an FDA-approved indication for weight management if they have obesity (BMI ≥30) or overweight with a weight-related comorbidity (BMI ≥27 with T2D, hypertension, dyslipidemia, or CVD). In these individuals, the two indications overlap and reinforce each other. For patients with type 2 diabetes, semaglutide (Ozempic) at diabetes doses also improves hepatic steatosis, though this dosage form is not specifically approved for MASH. Tirzepatide (Mounjaro, Zepbound) shows strong phase 2 evidence in MASH and phase 3 trials are underway; it is not yet FDA-approved for this liver indication and represents off-label use.

Patients with cirrhotic MASH (F4) were not included in the ESSENCE or SYNERGY-NASH trials and lie outside the current approved indications. Management of cirrhosis involves hepatology-specialist care focused on portal hypertension, varices, hepatocellular carcinoma surveillance, and liver transplant evaluation when appropriate. Resmetirom (Rezdiffra) holds a parallel non-cirrhotic MASH/F2-F3 approval based on the MAESTRO-NASH trial and may be combined with or used instead of semaglutide depending on individual circumstances and prescriber judgment.

Gastrointestinal adverse events — nausea, vomiting, constipation, diarrhea — are the most common side effects of semaglutide 2.4 mg and occurred at higher rates than placebo in the ESSENCE trial. They are typically most pronounced during the dose-escalation phase and tend to improve with continued use. Standard mitigation strategies include starting at the lowest dose, escalating slowly, eating smaller meals, and avoiding high-fat foods. Most patients can complete titration without discontinuing therapy, but patients with pre-existing significant gastroparesis should be monitored closely.

Histological confirmation of fibrosis stage before initiating semaglutide for the MASH indication is important for appropriate patient selection and for insurance coverage documentation. Treatment response — meaning fibrosis improvement or MASH resolution — cannot be reliably assessed without repeat liver biopsy or validated non-invasive testing. The ESSENCE trial evaluated outcomes at 72 weeks; longer-term data on hard outcomes such as cirrhosis prevention, liver-related events, and mortality will emerge as the trial continues its prespecified 240-week follow-up.

GLP-1 drugs treat MASH primarily through metabolic mechanisms: weight loss, insulin sensitization, and hepatic lipid reduction. They do not directly suppress the fibrogenic activity of hepatic stellate cells in the way that emerging anti-fibrotic drugs aim to. Patients who continue to consume alcohol, even at moderate levels, risk blunting hepatic benefit and accelerating fibrosis despite pharmacotherapy. Comprehensive MASH management should therefore address diet quality, alcohol abstinence, physical activity, and comorbid metabolic conditions — with GLP-1 therapy as a powerful adjunct, not a standalone solution.